👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Moderna files for U.S. authorization of COVID shot for kids under 6

Published 04/28/2022, 07:23 AM
Updated 04/28/2022, 01:21 PM
© Reuters. FILE PHOTO: A vial labelled "Moderna COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
PFE
-
TWTR
-
MRNA
-
BNTX
-

By Michael Erman and Julie Steenhuysen

(Reuters) - Moderna (NASDAQ:MRNA) Inc said on Thursday it asked U.S. regulators to authorize its COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.

The COVID-19 vaccine from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) is authorized for children 5 and older. But their trial results for 2- to 4-year-olds showed a weaker immune response than in adults, forcing the study to be extended to test a third dose. Pfizer has said that data would come in April.

"This does represent an important area of unmet need," Moderna Chief Medical Officer Paul Burton said in an interview.

"There's no other vaccine, no other therapy, that these little kids can have," Burton said. "If they do judge the data to be sufficient, I think from a public health perspective, offering it to these children as quickly as possible is the best thing."

Moderna released trial data in March showing that its vaccine was safe and generated a similar immune response in young children as for adults, which was the goal of the study.

The Omicron variant of the coronavirus, which has been shown to evade vaccine immunity compared with earlier versions, was predominant during the pediatric trial. The drugmaker said two doses were around 37% effective in preventing infections in 2- to 5-year-olds and 51% effective for children ages 6 months to 2 years.

Burton did not disclose a time frame for when the U.S. Food and Drug Administration was expected to consider the authorization request.

Top U.S. infectious disease expert Dr. Anthony Fauci suggested in an interview last week with CNN that the FDA hopes to review data from the Pfizer/BioNTech vaccine in the age group alongside the Moderna data.

It is not clear how many U.S. parents of will want to vaccinate their children in the age group. Only 28% of U.S. children in the 5 to 11 age group are fully vaccinated, and COVID-19 is often more mild in children than adults.

The U.S. Centers for Disease Control and Prevention released data on Tuesday showing that 75% of U.S. children had evidence of prior COVID infection in their blood, much of which occurred during the Omicron surge from December through February.

Still, Burton urged parents to vaccinate their children.

"COVID is a bad disease. These variants now are highly transmissible," he said.

"I do believe that getting vaccinated now should protect these kids: protect them against severe disease, hospitalization, protect them against the long-term effects of COVID. So it makes sense to get vaccinated," Burton added.

© Reuters. FILE PHOTO: A vial labelled

The American Academy of Pediatrics last week urged a swift review of the data in a Twitter (NYSE:TWTR) post, noting declines in other protections such as masking.

"With no known date for an authorized under 5 vaccine, we urge data once available to be submitted and reviewed ASAP so that we can offer a safe, effective vaccine to our littlest children."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.